Mohammad Vaziri Shares Breakthrough Insights on Factor XI Inhibitors for Thrombosis Prevention and Safer Anticoagulation
Mohammad Vaziri, Thoracic Surgery Professional at IRAN University of Medical Sciences (IUMS), posted on LinkedIn:
”Key points
Factor XI (FXI) inhibitors aim to uncouple hemostasis from thrombosis, presenting a novel approach to anticoagulation, with a reduced risk of bleeding compared with that associated with traditional anticoagulant agents.
Several phase II studies indicate that FXI inhibitors decrease thrombotic complications dose-dependently, without corresponding increases in bleeding, suggesting a favourable safety profile.
FXI inhibitors showed non-inferiority and potential superiority to low-molecular-weight heparin for the prevention of venous thromboembolism in patients undergoing orthopaedic surgery, with minimal bleeding risks observed at therapeutic doses.
Milvexian and abelacimab are theoretically promising for reducing the risk of bleeding associated with thromboprophylaxis in patients with atrial fibrillation; phase III clinical trials of safety and efficacy are ongoing.
In phase II trials involving patients with non-cardioembolic ischaemic stroke, no significant benefit of FXI inhibitors was found in terms of the primary ischaemic end points, but future phase III trials might find benefits in selected patients with large-vessel atherosclerosis.
The ongoing LIBREXIA-ACS trial will assess the use of milvexian in 16,000 patients with recent acute coronary syndrome.”
Reaf the full article here.
Title: Factor XI inhibitors for the prevention and treatment of venous and arterial thromboembolism
Authors: Davide Capodanno, John H. Alexander, M. Cecilia Bahit, John W. Eikelboom, C. Michael Gibson, Shaun G. Goodman, Vijay Kunadian, Gregory Y. H. Lip, Renato D. Lopes, Roxana Mehran, Shamir R. Mehta, Manesh R. Patel, Jonathan P. Piccini, Sunil V. Rao, Christian T. Ruff, P. Gabriel Steg, Jeffrey I. Weitz, Dominick J. Angiolillo
Stay updated with Hemostasis Today.
-
Sep 23, 2026, 13:58The New B12 Diagnostic Algorithm: From Serum Cobalamin to Functional Deficiency
-
Sep 23, 2026, 13:56Noha Soror: Preparing for Hematology and Medical Oncology Board Certification
-
Sep 23, 2026, 13:46Ugochi Ogu: What Can Platelet Proteomics Reveal about Pain and Neurocognitive Vulnerability in Sickle Cell Disease?
-
Sep 23, 2026, 13:42Melissa Hollo: Connecting Obesity and Anemia for Earlier Maternal Risk Intervention
-
Sep 23, 2026, 13:16Beverley Hunt: Advances in Haemostatic Management of Postpartum Haemorrhage
-
Sep 23, 2026, 13:13Ioanna Mela: Recruiting a Research Associate on DNA nanotechnology
-
Sep 23, 2026, 13:04Ben Samelson-Jones: Do Gene Variants Drive PK Differences in FIX-Fusion and N9-GP Therapies?
-
Sep 23, 2026, 12:57Shelly Reed: Advocating for HTCs and CDC Funding with the Hemophilia Federation of America
-
Sep 23, 2026, 12:51Domenico Girelli: How Verona Hospital Transformed ED Anemia Care with Patient Blood Management